Pathos AI, Inc.
About Pathos AI, Inc.
Pathos AI is an AI-enabled biotechnology company focused on re-engineering drug development by combining computational approaches across multimodal real-world data and patient-derived biological models. The clinical-stage company partners with pharmaceutical firms to advance precision medicines, with a pipeline that includes experimental oncology assets in-licensed from Novo Nordisk, Prelude Therapeutics and Rain Oncology. It operates from Chicago and maintains the website www.pathos.com.
- ๐ Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development
- ๐ Pathos AI raises $365M, becomes biotech unicorn | Kyle LaHucik posted on the topic | LinkedIn
- ๐ Pathos AI's $365M series D to fund trial of Novo tumor drug
- ๐ Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- ๐ Pathos - Products, Competitors, Financials, Employees, Headquarters Locations
Investors
Not disclosed in the source filing. Form D filings do not list investors โ StreetZero surfaces them from news where available.
Key highlights
- Raised $237.5 million via private placement in biotechnology.
- Platform combines AI with real-world data and patient-derived models for precision oncology.
- Pipeline includes assets sourced from Novo Nordisk and Prelude Therapeutics.
- Total funding reached $669 million after multiple rounds including a $365 million Series D.
Ask StreetZero about Pathos AI, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account